Real-time stock & option trading headlines, breaking news, rumors and strategy. Nothing we post constitutes investment advice; we may have positions in markets
$TRAW (-18.0% pre) U.K.’s Medicines and Healthcare Products Regulatory Agency issued a negative review of its Phase 2a influenza challenge study, forcing the postponement of a key trial for its lead antiviral candidate, tivoxavir marboxil.
ooc.bz/l/105131